THE FDG/PET METHODOLOGY FOR EARLY DETECTION OF DISEASE ONSET - A STATISTICAL-MODEL

被引:30
作者
CLARK, CM
AMMANN, W
MARTIN, WRW
TY, P
HAYDEN, MR
机构
[1] UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER V6T 1W5,BC,CANADA
[2] UNIV BRITISH COLUMBIA,DEPT NUCL MED,VANCOUVER V6T 1W5,BC,CANADA
[3] UNIV BRITISH COLUMBIA,DEPT MED,DIV NEUROL,VANCOUVER V6T 1W5,BC,CANADA
关键词
CEREBRAL GLUCOSE METABOLISM; HUNTINGTONS DISEASE;
D O I
10.1038/jcbfm.1991.44
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The development of appropriate statistical methodologies for neuroimaging studies is dependent upon the research question of interest. Often studies are analyzed with techniques that may not be appropriate for the research question but are accepted owing to convention, familiarity, or apparent statistical sophistication. Neuroimaging data are particularly complex owing to (a) the high number of potential dependent variables (i.e., regions of interest) coupled with the practical limitations on sample size; (b) the known physical properties of scanners (e.g., resolution) interacting with the intricate and variable structure of the human brain; and (c) mathematical properties introduced into the data by the physiological model for quantification. In this article, a statistical model will be discussed for addressing a particular problem in clinical studies. Given that there is a characteristic abnormality in regional glucose metabolism in a specific disease, can a probabilistic statement be made with confidence regarding the likelihood of an individual scan being similar to those from the disease group or normal subjects? The model capitalizes on known statistical aspects of normal regional glucose metabolism. To illustrate the model, data will be presented on normal subjects, patients with confirmed Huntington's disease, and subjects at risk for the disease. Reliability and clinical validity of the model will be discussed.
引用
收藏
页码:A96 / A102
页数:7
相关论文
共 17 条
[1]  
BROOKS RA, 1982, J NUCL MED, V23, P538
[2]  
CHASE TN, 1984, ANN NEUROL S1, V15, P5170
[4]   ALTERNATIVE STATISTICAL-MODELS FOR THE EXAMINATION OF CLINICAL POSITRON EMISSION TOMOGRAPHY FLUORODEOXYGLUCOSE DATA [J].
CLARK, C ;
CARSON, R ;
KESSLER, R ;
MARGOLIN, R ;
BUCHSBAUM, M ;
DELISI, L ;
KING, C ;
COHEN, R .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1985, 5 (01) :142-150
[5]  
CLARK CM, 1986, J CEREBR BLOOD F MET, V6, P756, DOI 10.1038/jcbfm.1986.132
[6]   GLUCOSE USE CORRELATIONS - A MATTER OF INFERENCE [J].
CLARK, CM ;
STOESSL, AJ .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1986, 6 (04) :511-512
[7]   POSITRON EMISSION TOMOGRAPHY IN SCHIZOPHRENIC-PATIENTS WITH AND WITHOUT NEUROLEPTIC MEDICATION [J].
DELISI, LE ;
HOLCOMB, HH ;
COHEN, RM ;
PICKAR, D ;
CARPENTER, W ;
MORIHISA, JM ;
KING, AC ;
KESSLER, R ;
BUCHSBAUM, MS .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1985, 5 (02) :201-206
[8]   ENGINEERING DEVELOPMENTS ON THE UBC-TRIUMF MODIFIED PETT-VI POSITRON EMISSION TOMOGRAPH [J].
EVANS, B ;
HARROP, R ;
HEYWOOD, D ;
MACKINTOSH, J ;
MOORE, RW ;
PATE, BD ;
ROGERS, JG ;
RUTH, TJ ;
SAYRE, C ;
SPRENGER, H ;
VANOERS, N ;
GUANG, YX .
IEEE TRANSACTIONS ON NUCLEAR SCIENCE, 1983, 30 (01) :707-710
[9]   THE COMBINED USE OF POSITRON EMISSION TOMOGRAPHY AND DNA POLYMORPHISMS FOR PRECLINICAL DETECTION OF HUNTINGTONS-DISEASE [J].
HAYDEN, MR ;
HEWITT, J ;
STOESSL, AJ ;
CLARK, C ;
AMMANN, W ;
MARTIN, WRW .
NEUROLOGY, 1987, 37 (09) :1441-1447
[10]   POSITRON EMISSION TOMOGRAPHY IN THE EARLY DIAGNOSIS OF HUNTINGTONS-DISEASE [J].
HAYDEN, MR ;
MARTIN, WRW ;
STOESSL, AJ ;
CLARK, C ;
HOLLENBERG, S ;
ADAM, MJ ;
AMMANN, W ;
HARROP, R ;
ROGERS, J ;
RUTH, T ;
SAYRE, C ;
PATE, BD .
NEUROLOGY, 1986, 36 (07) :888-894